PERSPECTA

News from every angle

← Back to headlines

Guggenheim Raises Price Target for Arcutis Biotherapeutics to $35

Guggenheim has increased its price target for Arcutis Biotherapeutics, Inc. (ARQT) to $35, maintaining a Buy rating for the biopharmaceutical company.

6 Mar, 15:20 — 6 Mar, 15:20
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual174d ago

Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating

Read full article →

Related Stories

Universal Studios Japan Announces Nearly $2 Billion Expansion Project

29m ago

Nvidia Reports Strong Q2 Earnings Driven by AI Demand Surge

46m ago

Nvidia Stock Rises as Bank of America Doubles Down on Bullish Forecast

51m ago

Canada Removes US Seafood from Retaliatory Tariff List Amid Trade Tensions

1h ago